Budesonide (B) undergoes an extensive biotransformation during the first pass metabolism in the liver to metabolites of low glucocorticoid activity. Surfactant (SF) (Survanta) can be used as a vehicle ...

Budesonide, a glucocorticoid, was proven to be a highly effective agent in preventing the development of lung tumors in A/J mice. In a lung tumor bioassay, budesonide produced 70% inhibition of tumor ...

San Antonio, Tex., - March 19, 2005 – New data indicated that earlier intervention with once-daily budesonide, an inhaled corticosteroid delivered by dry powder inhaler to children with mild ...

Budesonide is recommended as one of the first-line drugs for treatment of eosinophilic esophagitis (EoE), a chronic immune-mediated inflammatory disease, and in a recent study researchers updated a ...

March 17, 2009 — Budesonide nasal wash may be clinically effective in decreasing symptoms of chronic rhinosinusitis without suppression of the hypothalamic-pituitary-adrenal axis, according to the ...

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) SYMBICORT is a combination asthma medication that contains both an inhaled corticosteroid (ICS ...

If budesonide-formoterol were to become available over the counter (OTC) and used as-needed for mild asthma, it would save lives and cut healthcare costs, according to a computer modeling study ...

Contrary to other research findings, patients using the inhaled corticosteroid budesonide to treat Chronic Obstructive Pulmonary Disease (COPD) are not at increased risk of pneumonia, and the drug is ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) today announced the publication of data demonstrating that SYMBICORT Inhalation Aerosol 320/9 µg twice daily had a safety profile similar to ...

The Food and Drug Administration (FDA) granted emergency use authorizations (EUAs) for PCR tests, monoclonal antibodies, and vaccines. It is time to add a new weapon in this war and grant a similar ...

Please provide your email address to receive an email when new articles are posted on . The complete response letter (CRL) denied approval for budesonide oral suspension (BOS) and recommended ...